桂林三金：公司创新药平台主要为旗下孙公司宝船生物

Core Viewpoint - Guilin Sanjin (002275) is focusing on its innovative drug platform primarily through its subsidiary, Baoshan Biotech, which targets treatments for tumors and autoimmune diseases [1] Group 1: Company Overview - The company has a total of 17 research projects in progress, including 6 formal pipeline projects, 4 in the new drug discovery phase, 6 platform construction projects, and 1 pre-research project (which includes 27 sub-projects) [1] - The product BC006 monoclonal antibody injection is nearing completion of its Phase I clinical trial [1]